NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Tahereh Yavari: Antiphospholipid Syndrome — From Thrombosis to Thrombo-inflammation
Tahereh Yavari/LinkedIn
Oct 28, 2025, 06:50

Tahereh Yavari: Antiphospholipid Syndrome — From Thrombosis to Thrombo-inflammation

Tahereh Yavari, Rheumatology fellowship at Tehran University of Medical Sciences (TUMS), shared a post on LinkedIn:

“Antiphospholipid Syndrome (APS): From Thrombosis to Thrombo-inflammation — A New Era of Understanding

For decades, APS has been defined by thrombosis and pregnancy morbidity linked to antiphospholipid antibodies.
But the 2025 review by Zhu et al. in Frontiers in Immunology reframes APS as far more than a prothrombotic disorder — it’s an immune-driven vascular disease sitting at the crossroads of coagulation, inflammation, and autoimmunity.

Key Pathophysiologic Insights

  • aPL antibodies activate endothelial cells, platelets, monocytes, and neutrophils → amplifying tissue factor, complement, and NETosis.
  • The result is thrombo-inflammation — intertwined activation of clotting and innate immunity.
  • Recent work highlights the role of type I interferon signaling, oxidative stress, and metabolic reprogramming in sustaining vascular injury.

Therapeutic Shifts

  • Classic vitamin K antagonists (e.g., warfarin) remain the standard of care.
  • Direct Oral Anticoagulants (DOACs) are under investigation — promising convenience but still controversial, especially in triple-positive or arterial APS.
  • The real frontier lies beyond anticoagulation:
    • Targeting complement activation,
    • Blocking NET formation,
    • Modulating monocyte and endothelial activation.
  • These approaches reflect a shift toward treating APS as a thrombo-inflammatory syndrome, not just a clotting disorder.

Clinical Takeaway

  • Early recognition and integrated management are vital.
  • Future APS therapy will likely combine precision anticoagulation + immune modulation, guided by biomarkers of vascular inflammation.

The question is no longer “Which anticoagulant?”
It’s becoming “How do we stop the inflammatory cascade that drives thrombosis?”

Zhu Q-N, Qi X-B, et al. Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome. 2025.”

Stay updated with Hemostasis Today.

Anticoagulation Antiphospholipid Antibodies APS Clotting coagulation Direct Oral Anticoagulants Health Hematology Hemostasis Today Immune Modulation Immunology Medicine oxidative stress Pregnancy Morbidity Prothrombotic Disorder Tahereh Yavari thrombosis Vascular disease Warfarin
NewsFeed